Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

被引:0
作者
Margus Viigimaa
Helena Vaverkova
Michel Farnier
Maurizio Averna
Luc Missault
Mary E Hanson
Qian Dong
Arvind Shah
Philippe Brudi
机构
[1] Tallinn University of Technology,3rd Department of Internal Medicine
[2] Technomedicum,Department of Cardiology
[3] Medical Faculty and University Hospital Olomouc,undefined
[4] Point Medical - Rond Point de la Nation,undefined
[5] Dipartimento di Medicina Clinica e Patologie Emergenti Policlinico Paolo Giaccone Università di Palermo,undefined
[6] St Jan Hospital Department of Cardiology,undefined
[7] Global Scientific and Medical Publications,undefined
[8] Merck,undefined
[9] Late Development Statistics,undefined
[10] Merck,undefined
[11] Medical Affairs,undefined
[12] Merck,undefined
来源
Lipids in Health and Disease | / 9卷
关键词
Statin; Simvastatin; Rosuvastatin; Ezetimibe; High Cardiovascular Risk;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 151 条
[1]  
Graham I(2001)Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2486-2497
[2]  
Atar D(2007)European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 E1-40
[3]  
Borch-Johnsen K(2006)Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II Am Heart J 151 975-979
[4]  
Boysen G(2004)Rosuvastatin in the management of hyperlipidemia Clin Ther 26 1368-1387
[5]  
Burell G(2003)Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) Am J Cardiol 92 152-160
[6]  
Cifkova R(2007)European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 S1-113
[7]  
Dallongeville J(2009)EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries Eur J Cardiovasc Prev Rehabil 16 121-137
[8]  
De Backer G(2000)The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 459-467
[9]  
Ebrahim S(2010)Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets Int J Clin Pract 64 1052-1061
[10]  
Gjelsvik B(2009)Perspectives on low-density lipoprotein cholesterol goal achievement Curr Med Res Opin 25 431-447